On April 7, 2022 OBI Pharma, Inc. (TPEx: 4174) reported scientific data highlighting the antitumor synergy of OBI-3424 in combination with pembrolizumab (PD-1) and the association of high Globo H and PD-L1 expression resulting in poor survival in gastric cancer patients, will be presented at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting from April 8–13, 2022 in New Orleans, LA. (USA) (Press release, OBI Pharma, APR 7, 2022, View Source [SID1234611581]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
OBI’s Chief Scientific Officer, Ming-Tain Lai, Ph. D stated that "OBI Pharma is proud to present at the AACR (Free AACR Whitepaper) Annual Meeting our latest scientific findings on the efficacy of OBI-3424 and the role of the Globo H antigen. OBI-3424 can induce immunogenic cell death and demonstrated impressive synergistic efficacy in combination with Pembrolizumab in various cancer models. Emerging science also demonstrated poor survival in gastric cancer patients who have high Globo H and PD-L1 expression. These findings warrant potential combination therapeutic strategies of OBI-3424 as well as anti-Globo H plus PD-1/PD-L1 cancer therapeutics ".
Title: OBI-3424, an AKR1C3-activated prodrug, exhibits in vivo synergistic anti-tumor effect in combination with pembrolizumab by induction of immunogenic cell death
Poster number: 6111 / Abstract number: 2922
Authors1 : Chun-Chung Wang, Wan-Fen Li, Chih-Chan Lee, Lu-Tzu Chen, Jhih-Jie Yang, Jiann-Shiun Lai, Ming-Tain Lai.
1OBI Pharma, Inc., Taipei, Taiwan.
Title: High Globo-H expression associated with poor survival of gastric cancer patients and enriched PD-L1 expression
Poster Number: 6138 / Abstract number: 1742
Authors: Tzer-Min Kuo1, Hui-Ting Hsu2,3, Cheng-Yen Wei1, Ming-Tain Lai1 and Chun-Te Chen1
1 OBI Pharma, Inc., Taipei, Taiwan.
2 Department of Pathology, Changhua Christian Hospital, Changhua, Taiwan.
3 Institute and School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
The e-posters will be available for browsing at the AACR (Free AACR Whitepaper) Annual Meeting from 12:00 PM ET on April 8 and on the OBI Pharma website (www.obipharma.com) on April 9.